Acquires Berkeley, Calif.-based Oculinum Inc., maker of Oculinum (botulinum toxin type A), an approved treatment for ocular muscle disorders. The acquisition will allow Allergan to manufacture the product and conduct research and development. Allergan became a distributor for Oculinum in December 1989. In February, Oculinum, Inc. filed a PLA for the botulinum toxin product in the treatment of spasmodic torticollis. Oculinum is currently in Phase III trials for juvenile cerebral palsy.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth